Researchers presented preliminary findings at the American Heart Association's Scientific Sessions 2026 showing that adults aged 70 and older who have never had a heart attack or stroke may safely stop taking statins for at least two years without increased short-term cardiovascular risk.

The study enrolled 1,880 participants with an average age of 77, all taking statins for primary prevention and all with at least two chronic conditions. Researchers conducted the trial across 24 medical centers in Switzerland, France, and the Netherlands between November 2021 and April 2026. One group of 938 participants discontinued statins while 942 continued treatment.

Over approximately two years, participants who stopped statins showed no statistically significant increase in heart attacks, strokes, or deaths. Quality of life, muscle discomfort, falls, and muscle wasting were similar between groups. The researchers found roughly one additional cardiovascular event for every 40 people who stopped statins compared to those continuing treatment.

The longer follow-up revealed a different pattern. Over four years, 12.7% of participants who discontinued statins experienced a heart attack, stroke, or death, compared with 9.2% of those who continued taking medications.

"This small, increased risk of cardiovascular events means that one cannot make a general recommendation about stopping statins in this patient population," said study author Rita F. Redberg, M.D., M.Sc., FAHA, professor of cardiology at the University of California, San Francisco School of Medicine. "There should be shared decision-making between the patient and the healthcare professional to know if it is appropriate for an individual to discontinue the medication."

About 14% of participants switched from their assigned treatment approach during the study. Researchers performed additional statistical analyses to determine whether these changes affected findings. The results remained unchanged.

Redberg noted that the higher four-year cardiovascular event rate represents a new finding. She suggested the difference may have emerged because this trial included more participants and longer follow-up than earlier studies.